Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07712536 QY-201 Dermatitis, Atopic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07712536 clinical trial report covering QY-201, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20262686 Huoxuexiaoyi granules Endometriosis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
CTR20262686 clinical trial report covering Huoxuexiaoyi granules, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07716618 SAL0120 Chronic Kidney Diseases Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07716618 clinical trial report covering SAL0120, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07713329 Hydrogen Peroxide Tissue Adhesions Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07713329 clinical trial report covering Hydrogen Peroxide, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07716865 N-Acetylcysteine amide Cerebral Hemorrhage Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07716865 clinical trial report covering N-Acetylcysteine amide, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07717268 Enzalutamide Castration-Resistant Prostatic Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07717268 clinical trial report covering Enzalutamide, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600128472 Parthenolide Obesity Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
ChiCTR2600128472 clinical trial report covering Parthenolide, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07717177 Rituximab-Pvvr Large B-cell lymphoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07717177 clinical trial report covering Rituximab-Pvvr, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600128503 Cisplatin HPV positive oropharyngeal squamous cell carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
ChiCTR2600128503 clinical trial report covering Cisplatin, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07717242 Zeprumetostat Urothelial Carcinoma of the Urinary Bladder Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07717242 clinical trial report covering Zeprumetostat, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07716111 Retlirafusp alfa HER2 positive Gastroesophageal Junction Adenocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07716111 clinical trial report covering Retlirafusp alfa, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07717580 Lisaftoclax Primary Cutaneous Anaplastic Large Cell Lymphoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07717580 clinical trial report covering Lisaftoclax, Phase 2, endpoints, sponsor, geography, readout timing and development white space.